From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

  • Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. doi: 10.1093/cvr/cvab231.
Paul M Ridker  1
Affiliations
  • 1. Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.
PMID: 34352102 DOI: 10.1093/cvr/cvab231
Keywords
Atherosclerosis; C-reactive protein; Coronary artery disease; Cytokines; Inflammation; Interleukin-6.
Products